Paper Details

  1. Home
  2. Paper Details

TELO-SCOPE study: a randomised, double-blind, placebo-controlled, phase 2 trial of danazol for short telomere related pulmonary fibrosis.

Author: ApteSimon H, BancroftSandra, ChambersDaniel C, CorteTamera J, DickinsonJoanne L, EneverDebra, GlaspoleIan, GohNicole S, GraingeChristopher, HopkinsPeter, JaffeAdam, LutzkyViviana, MackintoshJohn A, PickettHilda A, PietschMaria, ReynoldsPaul N, SelvaduraiHiran, TanMaxine, WrobelJeremy, YerkovichStephanie T

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigates the safety and efficacy of danazol, an androgen, in treating pulmonary fibrosis (PF) associated with telomere shortening. Telomere shortening has been linked to PF, and danazol has shown potential in lengthening telomeres in blood cells. The study aims to assess danazol's effectiveness in improving PF symptoms in both adults and children.
Paper Details　
Original Abstract of the Article :
Recent discoveries have identified shortened telomeres and related mutations in people with pulmonary fibrosis (PF). There is evidence to suggest that androgens, including danazol, may be effective in lengthening telomeres in peripheral blood cells. This study aims to assess the safety and efficacy ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640666/

データ提供：米国国立医学図書館（NLM）

Danazol for Short Telomere-Related Pulmonary Fibrosis: A Potential New Treatment

Pulmonary fibrosis, a debilitating lung disease, is like a relentless desert wind, slowly eroding the body's ability to breathe. This study explores a potential new treatment approach for a specific form of pulmonary fibrosis linked to short telomeres, the protective caps on the ends of chromosomes. The researchers propose danazol, an androgen, as a potential treatment, as it has been shown to lengthen telomeres in blood cells.

Danazol: A Potential Treatment for Short Telomere-Related Pulmonary Fibrosis

The researchers are conducting a clinical trial to investigate the safety and efficacy of danazol in patients with pulmonary fibrosis associated with short telomeres. This study could lead to a new treatment option for this challenging disease.

Hope for Patients with Pulmonary Fibrosis

This research offers a glimmer of hope for patients with pulmonary fibrosis. Danazol, if proven effective, could provide a new avenue for treatment, potentially slowing disease progression and improving quality of life. However, it is important to note that this is still in the early stages of research, and further studies are needed to confirm its efficacy.

Dr. Camel's Conclusion

This research highlights the importance of understanding the underlying mechanisms of disease, like recognizing the signs of a looming sandstorm in the desert. By focusing on the telomere-shortening aspect of pulmonary fibrosis, this study opens a new avenue for treatment development. This research is a testament to the ongoing search for solutions to challenging medical conditions, a journey that resembles the endless pursuit of a desert oasis.

Date :
  1. Date Completed 2021-12-30
  2. Date Revised 2021-12-30
Further Info :

Pubmed ID

34857525

DOI: Digital Object Identifier

PMC8640666

Related Literature

Article Analysis
・Side Effects of danazol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.